Modelling long-term persistence of hepatitis B antibodies after vaccination

✍ Scribed by Vellinga, A.; Van Damme, P.; Bruckers, L.; Weyler, J.J.; Molenberghs, G.; Meheus, A.

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 74 KB
• Volume: 57
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/(sici)1096-9071(199902)57:2<100::aid-jmv2>3.0.co;2-m

✦ Synopsis

Antibody response to hepatitis B vaccination was measured in 97 institutionalized, mentally handicapped patients after a 0-, 1-, 6-month vaccination schedule. Two groups were formed at month 7 according to the antibody response, which determined whether they needed an additional vaccine dose at month 12, to achieve an antibody titre of 100 IU/liter. All residents were followed up yearly for the first 5 years, after which, they received another booster dose. Another blood sample was taken 11 years after the start of the program. A linear mixed-regression model was used to analyze the data. Random and fixed effects were included to determine the generally known risk factors and the still unknown individual characteristics that influence the titre of hepatitis B surface antibodies (anti-HBs). The mean anti-HBs titre was a function of time, type of mental retardation (Down's syndrome or other types of mental retardation), the use of antiepileptic drugs, and the additional booster at month 12. The immediate and vigorous response of the immune system to booster vaccination shows that the immunologic memory is good after primary vaccination. For the maintenance of protection, the recommendation for mentally retarded patients in institutions is vaccination of all seronegative residents as well as new entrants, after which, no additional boosters will be necessary.